1 – 32 of 32
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
The serotonergic system in L-DOPA-induced dyskinesia : pre-clinical evidence and clinical perspective
(
- Contribution to journal › Article
-
Mark
Animal models of l-DOPA-induced dyskinesia : the 6-OHDA-lesioned rat and mouse
(
- Contribution to journal › Article
- 2016
-
Mark
Production of dopamine by aromatic l-amino acid decarboxylase cells after spinal cord injury
(
- Contribution to journal › Article
-
Mark
Synthesis and antiproliferative activity of two diastereomeric lignan amides serving as dimeric caffeic acid-l-DOPA hybrids
(
- Contribution to journal › Article
-
Mark
Two-step production of monoamines in monoenzymatic cells in the spinal cord : A different control strategy of neurotransmitter supply?
(
- Contribution to journal › Scientific review
- 2014
-
Mark
Emerging pharmacotherapies for Parkinson's Disease: Experimental studies in the rat
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Novel strategies for enzyme replacement with gene therapy in models of Parkinson’s disease
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Chapter 22 - Rodent Models of Treatment-Related Complications in Parkinson Disease
2014) p.373-386(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2013
-
Mark
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia
(
- Contribution to journal › Article
- 2012
-
Mark
Synthesis of C-1 indol-3-yl substituted tetrahydroisoquinoline derivatives via a Pictet-Spengler approach
(
- Contribution to journal › Article
-
Mark
Duration of L-dopa and dopamine agonist monotherapy in Parkinson´s disease
(
- Contribution to journal › Article
-
Mark
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
(
- Contribution to journal › Scientific review
-
Mark
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels
(
- Contribution to journal › Article
-
Mark
Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain
(
- Contribution to journal › Scientific review
- 2011
-
Mark
Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate 1-DOPA-induced dyskinesia
(
- Contribution to journal › Article
- 2010
-
Mark
Involvement of non-dopaminergic systems in L-DOPA-induced dyskinsia
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias
(
- Contribution to journal › Article
-
Mark
Differential molecular and behavioural response to L-DOPA in mice injected with 6-hydroxydopamine in the striatum or in the medial forebrain bundle
2010)(
- Contribution to conference › Poster
- 2009
-
Mark
Gene therapy by enzyme replacement for Parkinson’s disease Optimization of continuous DOPA delivery and development of a candidate vector for clinical application
(
- Thesis › Doctoral thesis (compilation)
- 2008
-
Mark
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
(
- Contribution to journal › Article
- 2007
-
Mark
Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy.
(
- Contribution to journal › Scientific review
-
Mark
The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with l-DOPA: Relation to dose and route of administration.
(
- Contribution to journal › Article
-
Mark
Cell and Gene Therapy for Parkinson's Disease: Therapeutic Effect and Modulation of Dyskinesias in the 6-OHDA Rat Model
2007)(
- Thesis › Doctoral thesis (compilation)
-
Mark
Increased catechol-O-methyltransferase activity and protein expression in OX-42-positive cells in the substantia nigra after lipopolysaccharide microinfusion
(
- Contribution to journal › Article
- 2006
-
Mark
Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia.
(
- Contribution to journal › Article
-
Mark
Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
(
- Contribution to journal › Article
-
Mark
Intracellular signaling and cellular plasticity in a rat model of L-DOPA-induced dyskinesia
2006)(
- Thesis › Doctoral thesis (compilation)
- 2004
-
Mark
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
(
- Contribution to journal › Article
-
Mark
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
(
- Contribution to journal › Article
-
Mark
Modelling parkinsonian akinesia and dyskinesia in dopamine depleted rodents
2004)(
- Thesis › Doctoral thesis (compilation)
- 2003
-
Mark
Characterization of a new amino acid transport system in human epidermal Langerhans cells:
2003)(
- Thesis › Doctoral thesis (compilation)
- 2002
-
Mark
Toward a restorative therapy for Parkinson´s disease. Studies on the functional efficacy of intracerebral fetal cell transplants and GDNF delivery.
2002)(
- Thesis › Doctoral thesis (compilation)